查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466142

藥品製造市場：按配方、藥物開發類型、途徑、藥物、年齡層、分銷管道、治療領域 - 全球預測 2024-2030

Pharmaceutical Manufacturing Market by Formulation (Capsules, Injectable, Powders), Drug Development Type (In-House, Outsource), Route of Administration, Drugs, Age Group, Distribution Channel, Therapy Area - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年藥品製造市場規模為6,206.8億美元，預估2024年將達6,724.4億美元，2030年將達11.1017億美元，複合年成長率為8.66%。

藥品製造包括人類藥品和藥品的研究、開發、生產、行銷和分銷。這些產品旨在用於各種醫療保健環境中的疾病預防、診斷、治療和管理。主要最終使用者包括急性或慢性病患者、醫療保健專業人員、臨床試驗研究人員、保險公司和監管機構。人口老化加劇、慢性病盛行率高，以及針對世界各地未滿足的醫療需求對先進藥物的需求增加，正在影響製藥業的成長。政府增加的資金也支持醫療領域的研發活動，並使製藥公司能夠開發新藥。然而，國家當局嚴格的監管要求和漫長的臨床試驗過程給新藥製造商造成了進入障礙。

主要市場統計
基準年[2023] 6206.8億美元
預測年份 [2024] 6724.4億美元
預測年份 [2030] 11,101.70億美元
複合年成長率（%） 8.66%

此外，來自學名藥的競爭日益激烈以及維持強大的供應鏈已成為主要挑戰。此外，藥物開發過程中的技術進步和對個人化醫療日益成長的興趣正在為市場成長創造持續的機會。此外，引進數位技術來最佳化研發流程也提高了藥物開發效率。

配方：投資激增，支持注射配方的穩健研究和開發

膠囊因其易於吞嚥和劑量準確而受到青睞。膠囊適用於即時釋放和持續釋放製劑。此注射製劑繞過胃腸道吸收屏障，因此具有快速起效和高生物利用度。這些通常用於救命藥物、疫苗和生物製藥。粉末製劑非常適合吞嚥錠劑或膠囊有困難的患者，並且可以根據需要重新配製為方便的口服混懸劑或外用製劑。噴霧劑適合局部給藥，例如鼻腔或臉頰給藥。它吸收迅速，生物有效性度高，非常適合緊急給藥。混懸劑給藥彈性，適合吞嚥固態有困難的兒童及老年患者。由於其攜帶性、易於製造和成本效益，錠劑仍然是最受歡迎的劑型。每種劑型根據給藥途徑、起效時間、生物有效性、劑量準確性、易用性和患者偏好等因素滿足特定患者的需求。

藥品開發類型：委託藥品生產因成本效益而增加

內部藥物開發是指製藥公司在內部進行所有研發、臨床試驗、監管合規、生產、行銷和分銷。選擇這種方法的公司通常擁有全面的研發設施和熟練的人員，可以在受控環境中管理藥物開發過程的各個方面。外包涉及與外部組織（例如委託研究或製造組織）合作，以促進藥物開發過程的各個階段。外包合作夥伴可以提供從臨床前測試到上市後監測的廣泛服務。當公司缺乏特定藥物開發階段所需的設施或專業知識時，他們更喜歡外包。此外，外包可以利用第三方供應商的專業知識和資源來降低成本並加快上市時間。

給藥途徑: 由於慢性病的增加，活性化了腸外給藥的研究和開發

以吸入為基礎的藥物傳遞主要用於治療呼吸系統疾病，例如氣喘、囊腫纖維化和慢性阻塞性肺病。由於有針對性的肺部沉積，該途徑可以更快起效並提高安全性。口服給藥是最優選的途徑，因為它易於給藥、患者依從性、劑型的彈性和成本效益。腸外給藥包括靜脈（IV）、肌肉內（IM）和皮下（SC）注射，起效快，生物利用度為100%，非常適合緊急治療，是需要長期護理的慢性疾病的理想選擇。例如糖尿病和癌症。局部給藥特別適用於皮膚炎、乾癬和痤瘡等皮膚病的局部治療，以及塗布乳霜、凝膠和貼片直接塗抹到受影響區域來緩解疼痛。

藥物：非處方藥趨勢

非處方藥 (OTC) 對於為消費者提供常見疾病的有效治療方法至關重要。乙醯胺酚是一種廣泛使用的止痛藥，可緩解輕度至中度疼痛，並有效緩解多種情況下的發燒，包括頭痛、月經來潮、背痛、牙痛和關節炎。次水楊酸鉍是一種制酸劑和止瀉藥，用於治療常見的胃腸道疾病，如消化不良、胃灼熱、噁心和腹瀉。Dextromethorphan(DXM) 是一種止咳藥，可暫時緩解大腦髓質區域的咳嗽反射。Hydrocortisone乳膏是一種外用皮質類固醇，用於透過減輕發炎和搔癢來治療濕疹、皮膚炎和昆蟲叮咬等皮膚病。Ibuprofen通常用於緩解頭痛、牙痛、月經痛和肌肉骨骼損傷。假麻黃堿是一種鼻減充血劑，存在於許多感冒藥中，可透過縮小鼻道血管、減少腫脹和黏液積聚來緩解鼻塞。處方藥在由藥劑師配發之前必須得到醫療保健專業人員的核准。這些藥物通常用於治療較嚴重或慢性的疾病，需要專門的醫療介入以確保安全使用和最佳治療結果。對乙醯胺酚加氫可酮用於治療中度至重度疼痛。氨氯地平具有舒張血管和改善血流的作用，常用於治療高血壓和心絞痛。Lisinopril可擴張血管、降低血壓，用於治療高血壓。Metformin用於治療第 2 型糖尿病，以及飲食改變和運動計畫。Simvastatin可降低膽固醇水平並降低心肌梗塞等心血管疾病的風險。

年齡層：非常需要治療老年人疾病的製劑

成年人需要藥物來控制高血壓、糖尿病、心血管疾病和精神疾病等慢性疾病。最近的趨勢表明，對針對個人遺傳組成、生活方式因素和環境影響的個人化醫療的需求日益成長。對於兒童和青少年來說，由於學校強制免疫以及預防麻疹和水痘等兒童疾病，疫苗發揮重要作用。此外，為了確保兒童的用藥遵從性，需要考慮劑量準確性和偏好的兒童用製劑。人口老化面臨失智症、關節炎和骨質疏鬆等慢性疾病。藥物治療必須適合年齡，並仔細考慮藥物交互作用、副作用以及腎功能和肝功能的劑量調整。不同年齡層的藥品生產環境在藥物治療需求和偏好上有所不同。成人藥物治療著重於透過個人化方法管理慢性疾病，而兒童用製劑則著重於疫苗開發和依從性考量。在老年族群中，應特別注意由於老齡化相關的生理變化而導致的藥物交互作用和劑量調整。

通路：藥品非零售通路的普及

非零售分銷管道主要針對醫院、診所、政府機構、療養院和其他醫療機構。在這一領域，設施買家大量購買藥品，以滿足在這些設施內接受治療的患者的醫療需求。非零售分銷是首選，因為所需的特殊藥物無法透過零售通路輕易取得或在經濟上不可行。零售分銷透過線上和線下藥局、超級市場、藥局和通訊服務迎合個人消費者。客戶依靠零售分銷來快速、輕鬆地採購非處方藥 (OTC)、處方藥和其他醫療產品。此零售通路旨在為消費者提供廣泛的選擇、有競爭力的價格以及個人化服務，例如藥物諮詢和健康檢查。非零售部門專注於需要大量訂購特殊藥品的機構投資者，而零售部門則迎合尋求便利、可用性和多樣化產品的個人消費者。

治療領域：開發新癌症治療方法的技術創新浪潮

過敏性疾病的全球流行增加了對過敏治療和藥物的需求。由於人口迅速老化和不健康的生活方式導致心臟病的流行，對心血管治療的需求正在增加。壞血病、皮膚炎、皮膚感染疾病等皮膚病的增加需要高效率的藥物。由於糖尿病發生率不斷增加，需要有效的治療方法。胃腸道疾病的增加需要胃腸道治療和藥物的進步。感染疾病在世界各地廣泛傳播，需要不斷開發疫苗和抗病毒藥物。由於神經系統疾病的負擔日益增加，迫切需要改進藥物和治療方法。癌症仍然是死亡和受傷的主要原因，推動了對創新癌症治療的需求。人口老化正在增加眼科疾病的盛行率並增加對眼部護理的需求。慢性疼痛是全球性的負擔，需要有效的止痛藥和非類固醇消炎劑。精神疾病影響全世界數百萬人，需要在精神衛生保健上取得治療方法突破。慢性呼吸道疾病正在影響對新型肺部治療的需求。腎臟疾病呈上升趨勢，需要創新的腎臟治療方法。氣喘和慢性阻塞性肺病病例需要呼吸治療領域的進步。

區域洞察

美洲由於強大的研發能力、大型製藥企業的存在以及有利的政府政策，在全球醫藥市場中佔有重要地位。我們在美國擁有一家經 FDA 批准的生產工廠，專注於生產生技藥品和複雜的學名藥。德國、法國、瑞士和英國等歐洲國家都是擁有創新製造技術的先進製藥公司的所在地。這些製造商大力投資創新藥物療法，同時遵守歐洲藥品管理局所製定的嚴格監管標準。亞太舉措旨在促進國內生產和創新，鼓勵對研發和先進製造技術的投資。這項政策導致製藥公司新專利申請量迅速增加。此外，亞太地區私營和公共部門對醫療保健的投資增加刺激了藥品製造業。

FPNV定位矩陣

FPNV定位矩陣對於評估藥品製造市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限。最前線 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對藥品製造市場中供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該細分市場競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、碎片化主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：包括新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：包括對未來技術、研發活動以及突破性產品開發的智力見解。

本報告解決了以下關鍵問題：

1.醫藥製造市場的市場規模與預測是多少？

2.在藥品製造市場的預測期內，我們應該考慮投資哪些產品和應用？

3.藥品製造市場的技術趨勢和法規結構是什麼？

4.醫藥製造市場主要廠商的市場佔有率為何？

5.進入藥品製造市場的適當型態和策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球對疫苗和藥物的需求增加
      • 醫藥品研究開發費用增加
      • 老年人口增加和慢性病發生率增加
    • 抑制因素
      • 與藥品製造相關的高成本和複雜性
    • 機會
      • 加大醫藥製造領域投資金籌措力度
      • 新藥品製造技術的出現
    • 任務
      • 政府對製藥公司的嚴格監管
  • 市場區隔分析
    • 配方：投資激增以支持注射劑的強勁研發
    • 藥物開發類型：由於成本效益，外包藥物生產的使用增加
    • 給藥途徑：隨著慢性病盛行率的不斷增加，腸外給藥的研發活動不斷增加。
    • 藥物：成藥) 的趨勢
    • 年齡層：非常需要藥物處方來治療老年疾病
    • 分銷通路：藥品非零售通路的滲透
    • 治療領域：開發新腫瘤治療方法的創新浪潮
  • 市場趨勢分析
    • 美洲醫藥產業蓬勃發展，醫藥投資與出口快速成長
    • 政府對亞太地區國內製藥製造業的支持措施與投資
    • 主要製藥商正在向歐洲、中東和非洲擴張，重點是新藥的研發。
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析
  • 客戶客製化
    • 2022年最暢銷處方藥和非成藥排行榜

第6章 藥品製造市場：依配方分類

  • 介紹
  • 膠囊
  • 注射
  • 粉末
  • 噴
  • 暫停
  • 錠劑

第7章藥品製造市場：依藥物開發類型

  • 介紹
  • 公司內部
  • 外包

第8章 藥品製造市場：依管理途徑

  • 介紹
  • 吸入
  • 口服
  • 胃腸外的
  • 局部的

第9章藥品製造市場：依藥品分類

  • 介紹
  • 成藥
  • 處方藥

第10章藥品製造市場：依年齡層別

  • 介紹
  • 成人
  • 嬰兒和青少年
  • 老年人

第11章藥品製造市場：依通路分類

  • 介紹
  • 非零售
  • 零售

第12章藥品製造市場：依治療領域

  • 介紹
  • 過敏
  • 心血管疾病
  • 皮膚科
  • 糖尿病
  • 胃腸病學
  • 感染疾病
  • 神經病學
  • 腫瘤學
  • 眼科
  • 疼痛管理
  • 心理保健
  • 肺
  • 腎臟疾病
  • 呼吸系統疾病

第13章美洲藥品製造市場：按地區

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第14章亞太藥品製造市場：按地區

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第15章歐洲、中東和非洲藥品製造市場：按地區

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第16章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析

第17章競爭組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-22146147675F

[181 Pages Report] The Pharmaceutical Manufacturing Market size was estimated at USD 620.68 billion in 2023 and expected to reach USD 672.44 billion in 2024, at a CAGR 8.66% to reach USD 1,110.17 billion by 2030.

Pharmaceutical manufacturing comprises research, development, production, marketing, and distribution of drugs and medicinal products for human use. These products target disease prevention, diagnosis, treatment, and management in various healthcare settings. Key end-users include patients with acute or chronic illnesses, healthcare professionals, clinical trial researchers, insurance companies, and regulatory agencies. Rising aging populations with a higher prevalence of chronic diseases across the globe and increasing need for advanced medicines targeting unmet medical needs influence the growth in the pharmaceutical sector. In addition, rising government funding supports research and development activities in the healthcare sector, allowing new drug development for pharmaceutical companies. However, stringent regulatory requirements imposed by national authorities and the lengthy clinical trial processes create barriers to entry for new pharmaceutical manufacturers.

KEY MARKET STATISTICS
Base Year [2023] USD 620.68 billion
Estimated Year [2024] USD 672.44 billion
Forecast Year [2030] USD 1,110.17 billion
CAGR (%) 8.66%

Moreover, increasing competition from generics and biosimilars and maintaining a robust supply chain pose significant challenges. Furthermore, the technological advancements in drug development processes and a growing focus on personalized medicine create sustainable opportunities for market growth. Also, embracing digital technologies to optimize R&D processes, enhancing the drug development efficiency

Formulation: Surging investment to support robust research and development of injectable formulations

Capsules are preferred for their ease of swallowing and accurate dosing capabilities. They are suitable for both immediate-release and extended-release formulations. Injectable formulations offer rapid onset of action and high bioavailability as they bypass gastrointestinal absorption barriers. These are commonly used for life-saving medications, vaccines, and biopharmaceutical products. Powders are ideal for patients with difficulty swallowing tablets and capsules; they can be reconstituted into convenient oral suspensions and topical applications when needed. Sprays are preferred for localized drug delivery, such as nasal and buccal administration. They offer rapid absorption and high bioavailability, making them ideal for emergency medications. Suspensions provide flexibility in dosing and are suitable for pediatric and senior patients who have difficulty swallowing solid dosage forms. Tablets remain the most popular dosage form due to their portability, ease of manufacturing, and cost-effectiveness. Each formulation type serves specific patient needs based on factors such as administration route, onset of action, bioavailability, dosing accuracy, ease of use, and patient preferences.

Drug Development Type: Increasing use of outsourced pharmaceutical manufacturing due to its cost effectiveness

In-house drug development entails a pharmaceutical company conducting all research and development (R&D), clinical trials, regulatory compliance, production, marketing, and distribution within its organization. Companies that choose this approach often have comprehensive R&D facilities and skilled personnel to manage all aspects of the drug development process in a controlled environment. Outsourcing involves partnering with external organizations, such as contract research and manufacturing organizations, to facilitate various stages of the drug development process. Outsourcing partners may offer services ranging from preclinical studies to post-marketing surveillance. Companies prefer outsourcing if they lack the necessary facilities and expertise for specific drug development phases. Additionally, outsourcing can help control costs and reduce time-to-market by leveraging third-party vendors' specialized knowledge and resources.

Route of Administration: Rising research and development activities parenteral drug delivery with rising prevalence of chronic disease

Inhalation-based drug delivery is primarily preferred for treating respiratory disorders, including asthma, cystic fibrosis, and chronic obstructive pulmonary disease. This route offers a rapid onset of action and improved safety due to targeted lung deposition. Oral administration is the most favored route due to its ease of administration, patient compliance, flexibility in dosage forms, and cost-effectiveness. Parenteral drug delivery includes intravenous (IV), intramuscular (IM), and subcutaneous (SC) injections, offering rapid onset of action with 100% bioavailability, making it ideal for emergency treatments and chronic illnesses requiring long-term care, such as diabetes and cancer. Topical drug administration is particularly suitable for localized treatment of skin disorders such as dermatitis, psoriasis, and acne, and pain relief by applying creams, gels, and patches directly onto the affected area.

Drugs: Inclination toward Over-the-counter (OTC) drugs

Over-the-counter (OTC) drugs are vital in providing consumers with accessible and effective treatments for common ailments. Acetaminophen is a widely used analgesic and effectively relieves mild to moderate pain and alleviates fever in various conditions such as headaches, menstrual cramps, backaches, dental pain, and arthritis. Bismuth subsalicylate is an antacid and anti-diarrheal medication used to treat common gastrointestinal issues such as indigestion, heartburn, nausea, and diarrhea. Dextromethorphan (DXM) is a cough suppressant drug that temporarily relieves the cough reflex in the brain's medulla oblongata region. Hydrocortisone creams are topical corticosteroids designed to treat skin conditions, including eczema, dermatitis, and insect bites, by reducing inflammation and itching. Ibuprofen is commonly used to relieve headaches, dental pain, menstrual cramps, or musculoskeletal injuries. Pseudoephedrine is a nasal decongestant found in many cold medications and relieves congestion by narrowing blood vessels in the nasal passages and reducing swelling and mucus buildup. Prescription medicines require authorization from a healthcare professional before being dispensed by a pharmacist. These medications are often prescribed for more severe or chronic conditions where specialized medical intervention is necessary to ensure safe use and optimal therapeutic outcomes. Acetaminophen Plus Hydrocodone is used to manage moderate to severe pain. Amlodipine works by relaxing blood vessels and improving blood flow and is commonly prescribed for hypertension and angina. Lisinopril expands blood vessels, reduces blood pressure, and is prescribed for hypertension treatment. Metformin is prescribed for type 2 diabetes management alongside dietary changes and exercise programs. Simvastatin lowers cholesterol levels to reduce the risk of heart strokes and other cardiovascular problems.

Age Group: Significant need for drug formulations to treat geriatric medical conditions

Adults require medications for managing chronic conditions such as hypertension, diabetes, cardiovascular diseases, or mental health disorders. Recent trends indicate a growing need for personalized medicine that caters to individual genetic makeup, lifestyle factors, and environmental influences. For children & adolescents, vaccines play a vital role due to school immunization requirements and protection against childhood diseases, including measles or chickenpox. Additionally, there is a need for pediatric formulations that consider dosage accuracy and palatability to ensure medication adherence among children. The geriatric population faces chronic conditions such as dementia, arthritis, or osteoporosis. Medications must be age-appropriate with careful consideration of drug-drug interactions, side effects, and dosing adjustments based on renal and hepatic function. The pharmaceutical manufacturing landscape differs across various age groups regarding medication needs and preferences. While adult medications focus on managing chronic conditions with personalized approaches, pediatric formulations emphasize vaccine development and adherence considerations. Geriatric populations require special attention to drug interactions and dosage adjustments due to age-related physiological changes.

Distribution Channel: Penetration of non-retail distribution channels for pharmaceuticals

Non-retail distribution channels primarily cater to hospitals, clinics, government agencies, long-term care facilities, and other healthcare institutions. This segment involves bulk purchasing of pharmaceutical products by institutional buyers to meet the healthcare needs of patients receiving treatment within these establishments. The preference for non-retail distribution arises from the need for specialized medications that may not be readily available or economically viable through retail channels. Retail distribution caters to individual consumers through pharmacies both online and offline), supermarkets, drugstores, and mail-order services. Customers depend on retail distribution for over-the-counter (OTC) medications, prescription drugs, and other healthcare products that can be quickly and conveniently procured. Retail channels aim to offer consumers a wide range of options, competitive pricing, and personalized services such as medication counseling or health screenings. Non-retail focuses on institutional buyers that require bulk orders of specialized medications, while retail caters to individual consumers seeking convenience, accessibility, and a diverse product range.

Therapy Area: Wave of innovations toward development of new oncology treatment modalities

The increasing prevalence of allergic conditions worldwide drives the need for allergy treatment and drugs. The surge in aging populations and unhealthy lifestyles contributing to heart disease prevalence raises the need for cardiovascular therapies. The rise in a number of dermatology conditions, such as scurvy, dermatitis, and skin infections, necessitates efficient drugs. The rising diabetes epidemic creates a substantial need for effective therapies. Growth in gastrointestinal diseases necessitates advancements in gastroenterology treatments and medicines. Infectious diseases persist globally, requiring continuous vaccine and antiviral development. The rising burden of neurological disorders contributes to a significant need for improved drugs and therapeutics. Cancer remains a leading cause of casualties, driving the need for innovative oncology therapies. Aging populations contribute to increased eye disease prevalence and necessitate ophthalmic treatments. The global burden of chronic pain propels the need for effective analgesics or nonsteroidal anti-inflammatory drugs. Mental health disorders affect millions globally and require therapeutic breakthroughs within psychiatry. Chronic respiratory diseases influence the need for novel pulmonary treatments. The increasing prevalence of kidney disease requires innovative renal therapies. Cases of asthma and COPD necessitate advancements within the respiratory therapy area segment.

Regional Insights

The Americas hold a significant position in the global pharmaceutical market, attributed to its strong research & development (R&D) capabilities, presence of leading pharmaceutical companies, and favorable government policies. The United States has FDA-approved manufacturing facilities focusing on producing biologics and complex generics. European countries, including Germany, France, Switzerland, and the United Kingdom, have advanced pharmaceutical companies with innovative production technologies. These manufacturers have been investing heavily in innovative drug therapies while complying with stringent regulatory standards set by the European Medicines Agency. The Asia Pacific countries initiative aims to boost domestic production and innovation, encouraging investment in R&D and advanced manufacturing technologies. Their policies have led to a surge in new patents filed by pharmaceutical companies. Moreover, the rising investments in healthcare by the private and public sectors in the APAC region fueled the pharmaceutical manufacturing industry.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Pharmaceutical Manufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pharmaceutical Manufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Pharmaceutical Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Actiza Pharmaceutical Pvt. Ltd., Advent Pharma Ltd., Aenova Group GmbH, Amgen Inc., AstraZeneca PLC, Asymchem, Inc., Azurity Pharmaceuticals, Inc., Bayer AG, Biocon Limited, BioNTech SE, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, Emcure Pharmaceuticals Limited, F. Hoffmann-La Roche Ltd., Famar Group, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Johnson & Johnson Services, Inc., Lonza Group AG, Lupin Limited, McKesson Corporation, Merck KGaA, Moderna, Inc., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Piramal Pharma Limited, Recipharm AB, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., Veranova, L.P., and Zeon Lifesciences Ltd..

Market Segmentation & Coverage

This research report categorizes the Pharmaceutical Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Formulation
    • Capsules
    • Injectable
    • Powders
    • Sprays
    • Suspensions
    • Tablets
  • Drug Development Type
    • In-House
    • Outsource
  • Route of Administration
    • Inhalations
    • Oral
    • Parenteral
    • Topical
  • Drugs
    • Over-the-Counter (OTC) Medicines
    • Prescription Medicines
  • Age Group
    • Adults
    • Children & Adolescents
    • Geriatric
  • Distribution Channel
    • Non-Retail
    • Retail
  • Therapy Area
    • Allergy
    • Cardiovascular Diseases
    • Dermatology
    • Diabetes
    • Gastroenterology
    • Infectious Disease
    • Neurology
    • Oncology
    • Ophthalmology
    • Pain Management
    • Psychiatry
    • Pulmonary
    • Renal Disease
    • Respiratory Diseases
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Pharmaceutical Manufacturing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pharmaceutical Manufacturing Market?

3. What are the technology trends and regulatory frameworks in the Pharmaceutical Manufacturing Market?

4. What is the market share of the leading vendors in the Pharmaceutical Manufacturing Market?

5. Which modes and strategic moves are suitable for entering the Pharmaceutical Manufacturing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in global demand for vaccines and drugs
      • 5.1.1.2. Growing pharmaceutical R&D spending
      • 5.1.1.3. Growth in geriatric population and incidence rate of chronic disorders
    • 5.1.2. Restraints
      • 5.1.2.1. High costs and complexities associated with the pharma production
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in the investment and funding programs in the pharmaceutical manufacturing sector
      • 5.1.3.2. Emergence of novel pharmaceutical manufacturing technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations for pharmaceutical companies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Formulation: Surging investment to support robust research and development of injectable formulations
    • 5.2.2. Drug Development Type: Increasing use of outsourced pharmaceutical manufacturing due to its cost effectiveness
    • 5.2.3. Route of Administration: Rising research and development activities parenteral drug delivery with rising prevalence of chronic disease
    • 5.2.4. Drugs: Inclination toward Over-the-counter (OTC) drugs
    • 5.2.5. Age Group: Significant need for drug formulations to treat geriatric medical conditions
    • 5.2.6. Distribution Channel: Penetration of non-retail distribution channels for pharmaceuticals
    • 5.2.7. Therapy Area: Wave of innovations toward development of new oncology treatment modalities
  • 5.3. Market Trend Analysis
    • 5.3.1. Flourishing pharmaceutical industry and burgeoning pharmaceutical investment & exports in the Americas
    • 5.3.2. Supportive government initiatives and investments for domestic pharmaceutical manufacturing in the Asia-Pacific
    • 5.3.3. Emphasis on R&D of novel drugs and presence of significant pharmaceutical manufacturers in the EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis
  • 5.8. Client Customization
    • 5.8.1. List of Top Selling Prescription and Over-the-Counter Drugs in 2022

6. Pharmaceutical Manufacturing Market, by Formulation

  • 6.1. Introduction
  • 6.2. Capsules
  • 6.3. Injectable
  • 6.4. Powders
  • 6.5. Sprays
  • 6.6. Suspensions
  • 6.7. Tablets

7. Pharmaceutical Manufacturing Market, by Drug Development Type

  • 7.1. Introduction
  • 7.2. In-House
  • 7.3. Outsource

8. Pharmaceutical Manufacturing Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Inhalations
  • 8.3. Oral
  • 8.4. Parenteral
  • 8.5. Topical

9. Pharmaceutical Manufacturing Market, by Drugs

  • 9.1. Introduction
  • 9.2. Over-the-Counter (OTC) Medicines
  • 9.3. Prescription Medicines

10. Pharmaceutical Manufacturing Market, by Age Group

  • 10.1. Introduction
  • 10.2. Adults
  • 10.3. Children & Adolescents
  • 10.4. Geriatric

11. Pharmaceutical Manufacturing Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Non-Retail
  • 11.3. Retail

12. Pharmaceutical Manufacturing Market, by Therapy Area

  • 12.1. Introduction
  • 12.2. Allergy
  • 12.3. Cardiovascular Diseases
  • 12.4. Dermatology
  • 12.5. Diabetes
  • 12.6. Gastroenterology
  • 12.7. Infectious Disease
  • 12.8. Neurology
  • 12.9. Oncology
  • 12.10. Ophthalmology
  • 12.11. Pain Management
  • 12.12. Psychiatry
  • 12.13. Pulmonary
  • 12.14. Renal Disease
  • 12.15. Respiratory Diseases

13. Americas Pharmaceutical Manufacturing Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Pharmaceutical Manufacturing Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Pharmaceutical Manufacturing Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. INR 15,000 Crore Proposed in Pharma Sector, India
    • 16.3.2. Glenmark Pharma Launches Triple-Drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes
    • 16.3.3. Novo, Torrent may Widen Tie-Up
    • 16.3.4. U.S. FDA Approves Bristol Myers Squibb's Reblozyl (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
    • 16.3.5. Finnish Manufacturing Facility to Get EUR 50 Million Expansion
    • 16.3.6. Aenova and Galvita Enter Strategic Partnership
    • 16.3.7. Novo Nordisk Invests EUR 2.1 Billion in Hillerod Manufacturing Expansion
    • 16.3.8. Eli Lilly Adds USD 1.6 Billion to its Manufacturing Spending Plan in Indiana
    • 16.3.9. FDA Approves Novartis Millburn Facility for U.S. Commercial Production of Pluvicto
    • 16.3.10. Takeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in Japan
    • 16.3.11. Pfizer Acquires Abzena's Biologic Manufacturing Facility

17. Competitive Portfolio

  • 17.1. Key Company Profiles
  • 17.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PHARMACEUTICAL MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PHARMACEUTICAL MANUFACTURING MARKET DYNAMICS
  • FIGURE 7. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 18. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2023 VS 2030 (%)
  • FIGURE 20. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 24. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 26. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 29. PHARMACEUTICAL MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 30. PHARMACEUTICAL MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PHARMACEUTICAL MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY POWDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY POWDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SPRAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SPRAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY IN-HOUSE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OUTSOURCE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OUTSOURCE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INHALATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INHALATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OVER-THE-COUNTER (OTC) MEDICINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OVER-THE-COUNTER (OTC) MEDICINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PRESCRIPTION MEDICINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PRESCRIPTION MEDICINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ADULTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ADULTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CHILDREN & ADOLESCENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CHILDREN & ADOLESCENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GERIATRIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NON-RETAIL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NON-RETAIL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RETAIL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RETAIL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ALLERGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ALLERGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DERMATOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DIABETES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DIABETES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 69. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 70. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 71. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 72. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 73. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 74. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 75. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 76. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 77. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 78. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 79. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PSYCHIATRY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 80. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PSYCHIATRY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 81. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PULMONARY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 82. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PULMONARY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 83. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RENAL DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 84. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RENAL DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 85. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 86. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 87. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 88. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 89. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 92. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 93. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 94. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 95. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 96. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 97. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 98. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 99. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 100. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 101. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 102. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 103. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 104. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 105. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 108. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 109. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 110. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 111. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 112. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 113. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 116. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 117. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 118. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 119. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 122. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 123. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 124. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 125. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 126. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 127. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 128. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 129. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 130. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 131. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 132. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 133. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 136. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 137. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 138. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 139. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 140. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 141. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 142. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 143. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 144. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 145. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 146. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 147. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 150. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 151. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 152. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 153. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 154. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 155. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 156. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 157. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 158. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 159. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 160. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 161. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 164. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 165. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 166. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 167. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 168. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 169. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 170. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 171. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 172. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 173. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 174. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 191. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 192. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 193. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 196. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 197. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 198. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 199. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 200. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 201. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 202. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 203. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 204. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 205. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 206. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 207. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 210. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 211. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 212. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 213. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 214. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 215. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 216. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 217. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 218. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 219. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 220. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 221. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 224. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 225. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 226. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 227. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 228. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 229. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 230. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 231. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 232. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 233. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 234. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 235. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 238. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 239. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 240. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 241. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 242. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 243. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 244. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 245. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 246. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 247. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 248. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 249. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 252. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 253. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 254. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 255. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 256. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 257. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 258. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 259. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 260. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 261. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 262. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 263. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 266. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 267. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 268. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 269. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 270. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 271. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 272. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 273. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 274. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 275. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 276. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 277. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 280. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 281. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 282. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 283. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 284. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 285. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 286. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 287. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 288. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 289. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 290. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 291. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 294. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 295. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 296. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 297. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 298. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 299. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 300. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 301. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
  • TABLE 302. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
  • TABLE 303. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
  • TABLE 304. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
  • TABLE 305. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 308. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 309. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 310. SOUTH KOREA PHARMACEUTICAL MA